Human colorectal cancer cetuximab drug-resistant cell line and application thereof

A cetuximab, colorectal cancer technology, applied in the field of biomedicine, can solve the problem of lack of cetuximab-resistant colorectal cancer cell lines, etc., and achieve high scientific research and production application value

Active Publication Date: 2018-11-13
JIANGSU CANCER HOSPITAL
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, there is still a lack of colorectal cancer cell lines resistant to cetuximab, and the method of constructing tumor drug-resistant cell lines needs to be improved urgently

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Human colorectal cancer cetuximab drug-resistant cell line and application thereof
  • Human colorectal cancer cetuximab drug-resistant cell line and application thereof
  • Human colorectal cancer cetuximab drug-resistant cell line and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023] 1. Induction and establishment of human colorectal cancer cetuximab drug-resistant cell line NCI-H508 / C225

[0024] ① NCI-H508 cells were recovered and placed in RPMI-1640 medium containing 10% fetal bovine serum, at 37°C, 5% CO 2 Cultured in an incubator; in order to find the most suitable stimulating concentration of cetuximab, the NCI-H508 cells in the logarithmic growth phase were planted in 96-well culture dishes, and 0.1 μg / ml, 0.5 μg / ml, 1 μg / ml, 5μg / ml, 10μg / ml, 50μg / ml, 100μg / L cetuximab, after 72 hours, the cell viability was detected by the CCK-8 method, and the cell growth inhibition rate was calculated to obtain cetuximab The half inhibitory concentration (IC50) to NCI-H508 cell line.

[0025] ②NCI-H508 cells were stimulated for a long time with the IC50 value detected above at about 10 μg / ml, and after each stimulation for 72 hours, they were replaced with RPMI 1640 complete medium without cetuximab and cultured for 96 hours. After NCI-H508 cells can gr...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a human colorectal cancer cetuximab drug-resistant cell line, and belongs to the field of biomedical technology. The human colorectal cancer cetuximab drug-resistant cell linehas the advantages that a human colorectal cancer cell line NCI-H508 is treated by the cetuximab of different concentration, and the drug concentration for survival of 50% of cells is used as the initial concentration to treat the cells for a long time, until the cell NCI-H508 can normally grow under the concentration; the cell NCI-H508 is continued to treat for a long time by a gradual increasingmethod, the treatment duration is six months, and finally the human colorectal cancer cetuximab drug-resistant cell line NCI-H508 / C225 which can quickly grow under the treatment function of the cetuximab can be finally obtained; the human colorectal cancer cetuximab drug-resistant cell line can be used for analyzing the phenotypic change of morphology and biology after drug resistance of human colorectal cancer cetuximab, studying the molecule mechanism of the human colorectal cancer cetuximab drug resistance and the reversing drug resistance method, screening other anti-tumor drugs, findingthe tumor drug-resistant markers, and screening and evaluating the novel antitumor drugs and the like, and the scientific and research value and the production and application value are higher.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, and in particular relates to a cetuximab drug-resistant cell line of human colorectal cancer. Background technique [0002] Colorectal cancer (CRC) is one of the common malignant tumors of the digestive system, and its incidence rate ranks first among malignant tumors of the digestive system in my country. In recent years, with the changes in eating habits and lifestyles, the incidence of CRC has been increasing year by year, and the 5-year survival rate is low and the prognosis is poor. Most colorectal cancer patients are found at an advanced stage and lose the opportunity for surgery. [0003] Drug therapy is the main treatment for patients with advanced colorectal cancer, but drug resistance often occurs during treatment, which becomes the bottleneck of chemotherapy. Therefore, it is necessary to study the drug resistance mechanism of colorectal cancer cells and prevent or reverse the dr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C12N5/09C12Q1/02
CPCC12N5/0693C12N2500/84G01N33/5011
Inventor 井昶雯吴建中马蓉曹海霞王卓
Owner JIANGSU CANCER HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap